Preg-CoV

Evaluating COVID-19 Vaccines in Pregnancy

Brief Information Leaflet

What is this trial aiming to find out?

The Preg-CoV trial aims to identify the best interval to be used between doses of COVID-19 vaccines for protecting pregnant women against COVID-19.

The trial will compare COVID-19 vaccines that are currently being used in the UK vaccination programme, as well as new vaccines as they are approved.

Why are we doing this trial?

Ongoing global studies have found that pregnant women are more likely to develop severe COVID-19 disease compared to non-pregnant women of the same age. Pregnant women who develop COVID-19 symptoms are two to three times more likely to have their baby early. For these reasons, the current national recommendation in the UK is that COVID-19 vaccination should be offered to pregnant women at the same time as the rest of the population. However, further pregnancy-specific research into COVID-19 vaccines is urgently needed.

Who can take part?

- Pregnant women between 13-34 weeks gestation
- Aged 18-years or older
- Generally fit and well
- Have not received any COVID-19 vaccines *or* have only received one COVID-19 vaccine (either prior to pregnancy or in the first 13 weeks of pregnancy)

What does participation involve?

Participants who have not yet received any COVID-19 vaccines will be randomised to receive two doses in a short-time interval (4-6 weeks) or a long-time interval (8-12 weeks). For some participants they will receive their second dose after delivery. Participants will be blinded to the vaccine they receive. Some participants will also be blinded to the interval between doses by incorporating the whooping cough vaccine into the trial schedule.

Participants who have already received their first dose of a COVID-19 vaccine will receive one further dose of the same brand of COVID-19 vaccine in pregnancy.

There will be a minimum of 9 routine study visits and participants will be followed up until one year after their baby's birth. The majority of visits will happen at hospital and participants will be reimbursed up to £45 per visit.

Blood samples will be taken from participants throughout the study. Participants will also be asked to complete a symptom diary after each vaccination. A baby blood sample will be taken when babies are between 4-12 weeks old.

How do I find out more information?

If you would like more information about the trial, or to register interest via the online screening questionnaire, please visit:

https://vaccine.ac.uk/research/preg-cov-trial/

St George's University of London

Outstanding care every time

NHS
St George's University Hospitals
NHS Foundation Trust